Niels W.C.J. van de Donk

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.

Niels W.C.J. van de Donk, Gala Vega, Aurore Perrot et al. · Journal of Clinical Oncology · 2025 · 25 citations

OA-65 Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update

María-Victoria Mateos, Jesús F. San Miguel, Binod Dhakal et al. · Clinical Lymphoma Myeloma & Leukemia · 2024 · 24 citations

Hematological Malignancy, Oncology, Oa-65 Overall Survival +8

MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Leo Rasche, Carolina Schinke, Cyrille Touzeau et al. · Clinical Lymphoma Myeloma & Leukemia · 2024 · 13 citations

Hematological Malignancy, Medicine, Immunology +7

Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

Niels W.C.J. van de Donk, Alfred L. Garfall, Lotfi Benboubker et al. · Journal of Clinical Oncology · 2024 · 12 citations

Immunodeficiencies, Immunology, Immunotherapeutics +20